Financials and Corporate

Landmark co-development and commercialization agreement with AstraZeneca for IPH2201 in immuno-oncology Cash and cash equivalents amounting to €279 million following initial payment of $250 million...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) today announced that the co-development and commercialization agreement with AstraZeneca on Innate Pharma’s proprietary anti-NKG2A antibody...

Cash, cash equivalents and financial instruments of the Company amounted to 59.2 million euros as at March 31, 2015 Co-development and commercialization agreement with AstraZeneca including an upfront...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that during its Annual General Meeting (“AGM”) which took place on April 27, 2015, in Marseille, France : A number of 27,560,731 votes were...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) today announced that it has signed a co-development and commercialization agreement with AstraZeneca, along with MedImmune, its global biologics...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on April 27, 2015, at 11:00 am in its headquarters, 117 avenue de Luminy, F-13009...